Author/Authors :
Nasrallah, MacLean P. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Binder, Zev A. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Oldridge, Derek A. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Zhao, Jianhua Bioreference Laboratories, West Deptford, NJ, USA , Lieberman, David B. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Roth, Jacquelyn J. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Watt, Christopher D. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Sukhadia, Shrey University of Maryland School of Medicine, Baltimore, MD, USA , Klinman, Eva Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Daber, Robert D. Gnosity Consults, LLC, NJ, USA , Desai, Arati Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Brem, Steven Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , O’Rourke, Donald M. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA , Morrissette, Jennifer J. D. Perelman School of Medicine - University of Pennsylvania, Philadelphia, PA, USA
Abstract :
Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline for efficient and optimal workup of glioblastomas based on our routine performance of molecular testing. We describe our institution’s testing algorithm, assay development, and genetic findings in glioblastoma, to illustrate current practices and challenges in neuropathology related to molecular and genetic testing. We have found that coordination of test requisition, tissue handling, and incorporation of results into the final pathologic diagnosis by the neuropathologist improve patient care. Here, we present analysis of O6-methylguanine-DNA-methyltransferase promoter methylation and next-generation sequencing results of 189 patients, obtained utilizing our internal processes led by the neuropathology team. Our institutional pathway for neuropathologist-driven molecular testing has streamlined the management of glioblastoma samples for efficient return of results for incorporation of genomic data into the pathological diagnosis and optimal patient care.
